Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
Magrolimab联合阿扎胞苷与医生选择方案治疗未经治疗的TP53突变型急性髓系白血病:ENHANCE-2研究
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024027408
Zeidner, Joshua F; Sallman, David A; Récher, Christian; Daver, Naval G; Leung, Anskar Y H; Hiwase, Devendra K; Subklewe, Marion; Pabst, Thomas; Montesinos, Pau; Larson, Richard A; Wilde, Lindsay; Enjeti, Anoop K; Kawashima, Ichiro; Papayannidis, Cristina; O'Nions, Jenny; Johnson, Lisa; Dong, Mei; Huang, Julie; Bagheri, Taravat; Hacohen Kleiman, Gal; Lee, Calvin; Vyas, Paresh